Roger P. Smith

STUDY QUESTION: What is the safe and pharmacodynamically active dose range for PDC31 (prostaglandin F2α receptor inhibitor) in patients with primary dysmenorrhea (PD)? SUMMARY ANSWER: The 1 mg/kg/h dose of PDC31 appears to be safe and poten…

Primary dysmenorrhea, secondary dysmenorrhea, and cyclic pelvic pain syndromes represent a special subset of CPP. Although more common and no less debilitating, these conditions are better understood, more easily diagnosed, and more success…

A specially designed pain questionnaire can assist in the diagnosis and management of patients with ‘chronic pelvic pain’. Questionnaires used generally include information about demographics, a medical, sexual and marital history, an asses…

Assessment of cases of chronic pelvic pain presents a challenging problem, and many physicians overlook the association of sleep disorders and depression with such pain. We examined these linkages in our chronic pelvic pain clinic, using a …

Very few attempts to describe, codify , and implement analysis of intrauterine pressure data have occurred in the past. With a growing interest in intrauterine pressure during dysmenorrhea, the need for new ways of evaluating pressure data …